Participants
This study was conducted from April 2018 until November 2019 during
which 222 women were included into the PROVE biobank. Fifty-one women
did not have cognitive function assessments as they were included in the
biobank for other sub-studies. One hundred seventy-one women had
assessments for cognitive function. Eleven were excluded due to language
barriers. Seven women from the group of pre-eclampsia without severe
features were excluded as they developed renal impairment and/or HELLP.
Of the 153 included in the study, 61 had eclampsia, 28 had pre-eclampsia
complicated by pulmonary oedema, 38 had pre-eclampsia without severe
complications and 26 had normotensive pregnancies (Figure 1). The
majority had both subjective (n=140) and objective (n=139) assessments
performed. Both CFQ and MoCA tests were administered as close to
discharge as possible and none of the participants were treated with
magnesium sulphate at time of testing.